Taiwan International Graduate Program (TIGP) in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Trends Microbiol. 2016 Sep;24(9):739-749. doi: 10.1016/j.tim.2016.05.006. Epub 2016 Jun 7.
Hepatitis B virus (HBV) is a major human pathogen, and chronic hepatitis can lead to cirrhosis and malignant hepatocellular carcinoma. While HBV vaccine and treatment are available, it has remained a challenge to completely eradicate the virus from patients. Current therapy using either interferon or polymerase inhibitors cannot cure HBV with a high efficacy. Lifelong therapy is needed to suppress HBV in patients who achieve no seroconversion. Here, we review recent exciting advances of new strategies, including the inhibition of viral entry, the destruction or silencing of HBV covalently closed circular DNA (cccDNA), and breaking immune tolerance. Combinations of different therapeutic strategies could improve the cure rate of viral persistence in chronic hepatitis B.
乙型肝炎病毒 (HBV) 是一种主要的人类病原体，慢性乙型肝炎可导致肝硬化和恶性肝细胞癌。虽然有乙型肝炎疫苗和治疗方法，但要从患者体内完全清除病毒仍然是一个挑战。目前使用干扰素或聚合酶抑制剂的治疗方法并不能有效地治愈乙型肝炎。对于未能实现血清转换的患者，需要终身治疗来抑制乙型肝炎病毒。在这里，我们回顾了新策略的最新令人兴奋的进展，包括病毒进入的抑制、共价闭合环状 DNA (cccDNA) 的破坏或沉默，以及打破免疫耐受。不同治疗策略的联合应用可以提高慢性乙型肝炎病毒持续感染的治愈率。
